Privium Fund Management B.V. Purchases 2,900 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Privium Fund Management B.V. increased its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 45.7% during the fourth quarter, Holdings Channel.com reports. The firm owned 9,250 shares of the company’s stock after buying an additional 2,900 shares during the quarter. Krystal Biotech accounts for approximately 0.3% of Privium Fund Management B.V.’s holdings, making the stock its 29th biggest position. Privium Fund Management B.V.’s holdings in Krystal Biotech were worth $1,449,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Xponance Inc. lifted its stake in shares of Krystal Biotech by 9.5% in the fourth quarter. Xponance Inc. now owns 1,785 shares of the company’s stock valued at $280,000 after buying an additional 155 shares in the last quarter. Cibc World Markets Corp bought a new stake in shares of Krystal Biotech during the fourth quarter worth about $364,000. Commonwealth Equity Services LLC raised its holdings in shares of Krystal Biotech by 4.1% in the 4th quarter. Commonwealth Equity Services LLC now owns 4,866 shares of the company’s stock worth $762,000 after acquiring an additional 190 shares during the last quarter. Swiss National Bank lifted its position in Krystal Biotech by 8.4% in the 4th quarter. Swiss National Bank now owns 42,400 shares of the company’s stock valued at $6,642,000 after acquiring an additional 3,300 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Krystal Biotech by 31.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,054 shares of the company’s stock valued at $948,000 after purchasing an additional 1,440 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Price Performance

Shares of KRYS opened at $188.50 on Wednesday. Krystal Biotech, Inc. has a 1 year low of $141.72 and a 1 year high of $219.34. The stock’s fifty day moving average price is $164.69 and its two-hundred day moving average price is $173.58. The firm has a market cap of $5.43 billion, a PE ratio of 63.04 and a beta of 0.87.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. During the same period last year, the firm earned $0.30 EPS. Krystal Biotech’s revenue for the quarter was up 116.4% on a year-over-year basis. Sell-side analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In related news, CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This represents a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. Insiders own 14.10% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on KRYS shares. Jefferies Financial Group assumed coverage on Krystal Biotech in a research note on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price objective for the company. Citigroup increased their price target on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. HC Wainwright reaffirmed a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a report on Friday, February 28th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. Finally, Chardan Capital upped their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $220.00.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).